HALOZYME THERAPEUTICS, INC. (HALO) revenue & profit
HALOZYME THERAPEUTICS, INC. (HALO): revenue $1.4B, net income $316.9M in 2025; latest quarter +47.7% year over year. From SEC filings.
$1.4BRevenue 2025
TickerHALO (Nasdaq)
IndustryHealthcare · Biological Products, (No Diagnostic Substances)
Revenue 2025$1.4B
Net income 2025$316.9M
Net margin22.7%
Annual revenue growth+37.6%
Latest quarter (2026 Q2) · Revenue$481M
vs. same quarter last year+47.7%
Latest quarter · Net income$229.9M
Annual revenue & net income
| Year | Revenue | Net income | |
|---|---|---|---|
| 2022 | $660.1M | $202.1M | |
| 2023 | $829.3M | $281.6M | |
| 2024 | $1B | $444.1M | |
| 2025 | $1.4B | $316.9M |
ℹ️ Not investment advice. Calendar-year figures as tagged by the SEC; a company’s fiscal year may end in a different month.